In silico and in vitro arboviral MHC class I-restricted-epitope signatures reveal immunodominance and poor overlapping patterns
Flavivirus
Reverse vaccinology
DOI:
10.3389/fimmu.2022.1035515
Publication Date:
2022-11-17T07:40:51Z
AUTHORS (17)
ABSTRACT
Introduction The present work sought to identify MHC-I-restricted peptide signatures for arbovirus using in silico and vitro microarray tools. Methods First, an in-silico analysis of immunogenic epitopes restricted four the most prevalent human MHC class-I was performed by identification affinity score. For that, more than 10,000 sequences from 5 Arbovirus 8 different viral serotypes, namely Zika (ZIKV), Dengue (DENV serotypes 1-4), Chikungunya (CHIKV), Mayaro (MAYV) Oropouche (OROV) viruses, addition YFV were analyzed. Haplotype HLA-A*02.01 dominant all arboviruses. Over one thousand HLA-A2 peptides employed build a comprehensive identity matrix. Intending assess HLAA*02:01 reactivity vitro, designed generated dimeric protein containing HLA-A*02:01. Results matrix allowed only three overlapping between two or flavivirus sequences, suggesting poor virus-specific amongst arborviruses. Global fluorescence intensity peptide-HLA-A*02:01 binding indicated dose-dependent effect array. Considering assessed arboviruses, number DENV-derived with HLA-A*02:01 highest. Furthermore, lower YFV-17DD presented when compared non-overlapping peptides. In addition, assessment HLA-A*02:01-reactive across virus polyproteins highlighted non-structural proteins as “hot-spots”. Data supported these findings showing presence major hydrophobic sites final segment 1 throughout 2a (Ns2a) nonstructural 2b (Ns2b), 4a (Ns4a) 4b (Ns4b). Discussion To our knowledge, results provide detailed snapshot immunodominant signature MHC-class I restriction, which may bring insight into design future vaccines arboviruses vaccination protocols highly endemic areas.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (63)
CITATIONS (7)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....